Accelerating translational research through Cardiff University’s Clinical Innovation pipeline

Lead Research Organisation: Cardiff University

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Bennasar M (2018) Automated Assessment of Movement Impairment in Huntington's Disease. in IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society

publication icon
Bennasar M (2016) Huntington's Disease Assessment Using Tri Axis Accelerometers in Procedia Computer Science

 
Description "Mechanical Loading in Disease (MeLoDi)"
Amount £99,820 (GBP)
Funding ID NC/C016103/1 
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts'
Amount £127,762 (GBP)
Organisation QBiotics 
Sector Private
Country Australia
Start 01/2018 
End 12/2020
 
Description 'Repurposing ingenol mebutate as a novel pharmaceutical therapy for dermal fibrosis'
Amount £49,995 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2017
 
Description Development of TheraNostic ProTides
Amount £48,709 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2020 
End 12/2020
 
Description Investigating a candidate biomarker of osteoarthritis: Role in pathogenesis and efficacy to diagnose disease.
Amount £60,000 (GBP)
Organisation Cardiff University 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2021
 
Description Life Sciences Bridging Fund
Amount £51,000 (GBP)
Organisation Government of Wales 
Sector Public
Country United Kingdom
Start 07/2017 
End 02/2018
 
Description PACE-HD
Amount £411,000 (GBP)
Organisation Gossweiler Foundation 
Sector Charity/Non Profit
Country Switzerland
Start 01/2018 
End 01/2020
 
Description Role of protein kinase C (PKC) isoforms and downstream signalling pathways in mediating the anti-scarring effects of ingenol mebutate in dermal fibroblasts-myofibroblasts
Amount £110,000 (GBP)
Organisation Government of Kuwait 
Sector Public
Country Kuwait
Start 10/2020 
End 09/2023
 
Description Synovial joint in vitro model that is scalable for medium throughput screening applications.
Amount £51,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 04/2019
 
Description Validation of a stem cell derived cartilage model for osteoarthritis research and drug screening.
Amount £86,000 (GBP)
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 09/2021
 
Description kinase selectivity panel profiling
Amount £5,000 (GBP)
Organisation Life Sciences Research Network Wales 
Sector Academic/University
Country United Kingdom
Start 08/2018 
End 11/2018
 
Description DA Bioventix 
Organisation Bioventix
Country United Kingdom 
Sector Private 
PI Contribution Currently interacting with (Bioventix, Farnham)in relation to commercialisation of our 'technology'. There is interest both in using our cartilage model as a screening platform as well as in the candidate biomarkers.
Collaborator Contribution Novel mAbs
Impact n/a
Start Year 2018
 
Description DA UCB 
Organisation UCB Pharma
Department Cellular Sciences - UCB Pharma
Country United Kingdom 
Sector Private 
PI Contribution Currently interacting with (UCB Pharma, Slough) in relation to commercialisation of our 'technology'. There is interest both in using our cartilage model as a screening platform as well as in the candidate biomarkers.
Collaborator Contribution Novel MAbs
Impact n/a
Start Year 2018
 
Description Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts 
Organisation QBiotics
Country Australia 
Sector Private 
PI Contribution 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts'
Collaborator Contribution 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts'
Impact n/a
Start Year 2012
 
Description Leo Pharma 
Organisation LEO Pharma (including subsidiary Peplin Ltd)
Country Denmark 
Sector Private 
PI Contribution now in the process of discussing further in vitro / ex vivo research work and funding options with LEO Pharma, to be undertaken in the foreseeable future.
Collaborator Contribution Industry guidance and in kind contributions
Impact n/a
Start Year 2016
 
Description Novartis collaboration 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution REPURPOSING LICENSED DRUGS FOR TREATMENT OF INJURY-INDUCED OSTEOARTHRITS.
Collaborator Contribution Key reagent is supplied free of charge under MTA with Novartis.
Impact n/a
Start Year 2017
 
Description  
IP Reference  
Protection Copyrighted (e.g. software)
Year Protection Granted
Licensed Yes
Impact Secondary outcome measures
 
Description 'Biological interventions for post-traumatic osteoarthritis' 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker presentation
Year(s) Of Engagement Activity 2019
 
Description Workshop with KOLs 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact Scoping of commercial opportunities
Year(s) Of Engagement Activity 2018